Fluconazole Dosing for Candidemia
For candidemia in adults, administer fluconazole 800 mg (12 mg/kg) loading dose on day 1, followed by 400 mg (6 mg/kg) daily maintenance dose, with dose reduction to 50% of the maintenance dose for patients with creatinine clearance ≤50 mL/min (excluding hemodialysis). 1, 2
Standard Dosing Regimen
The IDSA 2016 guidelines and FDA labeling establish the following dosing framework 1, 2:
- Loading dose: 800 mg (12 mg/kg) on day 1
- Maintenance dose: 400 mg (6 mg/kg) once daily
- Duration: Continue for 2 weeks after documented clearance of Candida from bloodstream and resolution of symptoms 1
This regimen applies specifically to patients with fluconazole-susceptible isolates (MIC ≤2 mg/L). Note that echinocandins remain the preferred first-line therapy for most candidemia cases; fluconazole is appropriate for step-down therapy or in patients unlikely to have fluconazole-resistant species 1.
Renal Impairment Adjustments
Fluconazole is primarily renally excreted (80% unchanged), making dose adjustment critical in renal dysfunction 2, 3:
Dosing Algorithm by Creatinine Clearance:
- CrCl >50 mL/min: Full dose (800 mg loading, then 400 mg daily)
- CrCl ≤50 mL/min (no dialysis): 800 mg loading dose, then 200 mg daily (50% reduction)
- Hemodialysis: 800 mg loading dose, then 400 mg after each dialysis session; on non-dialysis days, give 200 mg 2
Important Caveats:
Weight-based dosing is more accurate than fixed dosing, particularly in obese patients and those with altered renal function 4, 5, 6. A 2007 study found that 55% of patients receiving empiric fluconazole and 47% receiving targeted therapy had inadequate dosing, with increased body weight and preserved renal function (CrCl >50 mL/min) being significant predictors of underdosing 4. This occurs because fixed 400 mg doses fail to achieve 6 mg/kg in heavier patients.
Special Populations
Critically Ill Patients on CRRT/ECMO:
Recent evidence demonstrates substantial pharmacokinetic alterations in patients receiving continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) 5, 7. Standard guideline dosing (12 mg/kg loading, 6 mg/kg maintenance) achieves adequate target attainment only for Candida species with MIC ≤1 mg/L in these patients 5.
For CRRT patients, fluconazole clearance is significantly influenced by:
- Dialysate flow rates
- Filter characteristics
- Residual renal function
Consider higher maintenance doses (up to 12 mg/kg daily) in patients on moderate-to-high intensity CRRT to achieve AUC/MIC >100, particularly for organisms with MIC approaching 2 mg/L 7.
Neonates:
For systemic candidiasis in neonates, the dosing differs substantially 1, 2:
- Age ≥3 months: 25 mg/kg loading dose (max 800 mg), then 12 mg/kg daily (max 400 mg)
- Age <3 months, gestational age ≥30 weeks: 25 mg/kg loading, then 12 mg/kg daily
- Age <3 months, gestational age <30 weeks: 25 mg/kg loading, then 9 mg/kg daily
Common Pitfalls to Avoid
Failure to give loading dose: Without the loading dose, steady-state concentrations are not achieved until day 5-7, delaying therapeutic effect 2
Inadequate dosing in obese patients: Fixed 400 mg doses frequently underdose patients >67 kg. Always calculate weight-based dosing 4
Forgetting renal dose adjustment: Fluconazole accumulates rapidly in renal impairment, with half-life extending from 37 hours (normal function) to 102 hours (severe impairment) 3, 8
Using fluconazole for C. glabrata without susceptibility data: C. glabrata requires higher doses (12 mg/kg daily) and often demonstrates dose-dependent susceptibility or resistance 1, 4
Premature discontinuation: Treatment must continue for minimum 2 weeks AFTER blood culture clearance, not from initiation 1
Ignoring CRRT parameters: Standard dosing may be inadequate in patients on CRRT, particularly with higher dialysate flow rates 5, 7
Pharmacokinetic/Pharmacodynamic Target
The therapeutic target is AUC₀₋₂₄/MIC ratio >100 for maximal efficacy 5, 7. This target is reliably achieved with standard dosing for susceptible organisms (MIC ≤1 mg/L) but may require dose escalation for MIC values of 2 mg/L, particularly in patients with augmented renal clearance or those receiving CRRT 5, 6.